Genetic Analysis AS (XSAT:GEAN)
Sweden · Delayed Price · Currency is SEK · Price in NOK 0.6400
-0.0100 (-1.54%)
At close: Jun 11, 2026
Genetic Analysis AS Income Statement
Financials in millions NOK. Fiscal year is January - December.
Millions NOK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 18.16 | 16.71 | 15.89 | 14.15 | 11.16 | 6.8 |
Other Revenue | 3.39 | 4.46 | 4.8 | 9.02 | 9.58 | 6.58 |
| 21.55 | 21.17 | 20.68 | 23.16 | 20.75 | 13.38 | |
Revenue Growth (YoY) | 8.14% | 2.36% | -10.71% | 11.65% | 55.08% | 77.51% |
Cost of Revenue | 5.34 | 4.7 | 3.11 | 4.6 | 3.91 | 1.28 |
Gross Profit | 16.21 | 16.47 | 17.57 | 18.57 | 16.84 | 12.1 |
Selling, General & Admin | 13.18 | 13.8 | 16.83 | 20.72 | 22.31 | 20.39 |
Other Operating Expenses | 8.9 | 8.48 | 9.99 | 16.23 | 17.88 | 16.05 |
Operating Expenses | 27.16 | 27.45 | 32.06 | 42.52 | 45.02 | 40.97 |
Operating Income | -10.95 | -10.98 | -14.49 | -23.96 | -28.18 | -28.87 |
Interest Expense | -1.25 | -0.5 | -0.36 | -0.25 | -0.12 | -0.13 |
Interest & Investment Income | 1.06 | 0.35 | 0.42 | 0.36 | 0.03 | - |
Earnings From Equity Investments | - | - | -0.62 | -0.09 | - | - |
Currency Exchange Gain (Loss) | -0.29 | -0.29 | 0.27 | 0.03 | - | - |
Other Non Operating Income (Expenses) | -0 | 0 | -0 | 0.09 | -0 | - |
EBT Excluding Unusual Items | -11.43 | -11.41 | -14.77 | -23.82 | -28.27 | -29.01 |
Pretax Income | -11.43 | -11.41 | -14.77 | -23.82 | -28.27 | -29.01 |
Net Income | -11.43 | -11.41 | -14.77 | -23.82 | -28.27 | -29.01 |
Net Income to Common | -11.43 | -11.41 | -14.77 | -23.82 | -28.27 | -29.01 |
Shares Outstanding (Basic) | 68 | 63 | 45 | 26 | 25 | 25 |
Shares Outstanding (Diluted) | 68 | 63 | 45 | 26 | 25 | 25 |
Shares Change (YoY) | 46.42% | 41.67% | 70.99% | 4.61% | 0.07% | 45.72% |
EPS (Basic) | -0.17 | -0.18 | -0.33 | -0.91 | -1.13 | -1.16 |
EPS (Diluted) | -0.17 | -0.18 | -0.33 | -0.91 | -1.13 | -1.16 |
Free Cash Flow | -1.4 | 2.05 | -12.08 | -17.38 | -19.69 | -27.7 |
Free Cash Flow Per Share | -0.02 | 0.03 | -0.27 | -0.66 | -0.79 | -1.11 |
Gross Margin | 75.23% | 77.80% | 84.95% | 80.15% | 81.17% | 90.42% |
Operating Margin | -50.81% | -51.86% | -70.03% | -103.41% | -135.84% | -215.80% |
Profit Margin | -53.05% | -53.91% | -71.40% | -102.82% | -136.28% | -216.80% |
Free Cash Flow Margin | -6.52% | 9.68% | -58.41% | -75.02% | -94.88% | -207.07% |
EBITDA | -10.85 | -10.78 | -14.29 | -23.77 | -28 | -28.7 |
EBITDA Margin | -50.34% | -50.92% | -69.07% | -102.61% | -134.95% | -214.56% |
D&A For EBITDA | 0.1 | 0.2 | 0.2 | 0.19 | 0.19 | 0.17 |
EBIT | -10.95 | -10.98 | -14.49 | -23.96 | -28.18 | -28.87 |
EBIT Margin | -50.81% | -51.86% | -70.03% | -103.41% | -135.84% | -215.80% |
Revenue as Reported | 21.55 | 21.17 | 20.68 | 23.16 | 20.75 | 13.38 |